Literature DB >> 18495376

Local recurrence in rectal cancer: anatomic localization and effect on radiation target.

Erik Syk1, Michael R Torkzad, Lennart Blomqvist, Per J Nilsson, Bengt Glimelius.   

Abstract

PURPOSE: To determine the sites of local recurrence after total mesorectal excision for rectal cancer in an effort to optimize the radiation target. METHODS AND MATERIALS: A total of 155 patients with recurrence after abdominal resection for rectal cancer were identified from a population-based consecutive cohort of 2,315 patients who had undergone surgery by surgeons trained in the total mesorectal excision procedure. A total of 99 cross-sectional imaging studies were retrieved and re-examined by one radiologist. The clinical records were examined for the remaining patients.
RESULTS: Evidence of residual mesorectal fat was identified in 50 of the 99 patients. In 83 patients, local recurrence was identified on the imaging studies. All recurrences were within the irradiated volume if the patients had undergone preoperative radiotherapy or within the same volume if they had not. The site of recurrence was in the lower 75% of the pelvis, anatomically below the S1-S2 interspace for all patients. Only 5 of the 44 recurrences in patients with primary tumors >5 cm from the anal verge were in the lowest 20% of the pelvis. Six recurrences involved the lateral lymph nodes.
CONCLUSION: These data suggest that a lowering of the upper limit of the clinical target volume could be introduced. The anal sphincter complex with surrounding tissue could also be excluded in patients with primary tumors >5 cm from the anal verge.

Entities:  

Mesh:

Year:  2008        PMID: 18495376     DOI: 10.1016/j.ijrobp.2008.01.063

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  The Perfect Total Mesorectal Excision Obviates the Need for Anything Else in the Management of Most Rectal Cancers.

Authors:  Richard John Heald; Ines Santiago; Oriol Pares; Carlos Carvalho; Nuno Figueiredo
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 2.  Update on advances and controversy in rectal cancer treatment.

Authors:  S Biondo; D Fraccalvieri; T Golda; R Frago; L Trenti; E Kreisler
Journal:  Tech Coloproctol       Date:  2016-01-12       Impact factor: 3.781

3.  Small bowel protection in IMRT for rectal cancer : A dosimetric study on supine vs. prone position.

Authors:  Julia Koeck; Katharina Kromer; Frank Lohr; Tobias Baack; Kerstin Siebenlist; Sabine Mai; Sylvia Büttner; Jens Fleckenstein; Frederik Wenz
Journal:  Strahlenther Onkol       Date:  2017-02-20       Impact factor: 3.621

Review 4.  Mesentery in Transanal TME.

Authors:  Joep Knol; Sami A Chadi
Journal:  Clin Colon Rectal Surg       Date:  2022-08-10

Review 5.  Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers.

Authors:  Jia-Yuan Peng; Zhong-Nan Li; Yu Wang
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 6.  Neo-adjuvant radiotherapy in rectal cancer.

Authors:  Bengt Glimelius
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

7.  Systematic review of classification systems for locally recurrent rectal cancer.

Authors:  Z Rokan; C Simillis; C Kontovounisios; B J Moran; P Tekkis; G Brown
Journal:  BJS Open       Date:  2021-05-07

8.  Value of MRI and diffusion-weighted MRI for the diagnosis of locally recurrent rectal cancer.

Authors:  Doenja M J Lambregts; Vincent C Cappendijk; Monique Maas; Geerard L Beets; Regina G H Beets-Tan
Journal:  Eur Radiol       Date:  2011-01-16       Impact factor: 5.315

9.  Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review.

Authors:  Michael R Torkzad; Lars Påhlman; Bengt Glimelius
Journal:  Insights Imaging       Date:  2010-08-15

10.  Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.

Authors:  Bengt Glimelius
Journal:  Ups J Med Sci       Date:  2012-05       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.